Smith PJ - Search Results

1

Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.

Smith PJ, van Dyk J, Fredericks A. Smith PJ, et al. Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S325-8; discussion S351-2. Int J Tuberc Lung Dis. 1999. PMID: 10593712

2

Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.

Zent C, Smith P. Zent C, et al. Tuber Lung Dis. 1995 Apr;76(2):109-13. doi: 10.1016/0962-8479(95)90551-0. Tuber Lung Dis. 1995. PMID: 7780091 Clinical Trial.

3

Comprehensive assay for pyrazinamide, rifampicin and isoniazid with its hydrazine metabolites in human plasma by column liquid chromatography.

Walubo A, Smith P, Folb PI. Walubo A, et al. J Chromatogr B Biomed Appl. 1994 Aug 19;658(2):391-6. doi: 10.1016/0378-4347(94)00230-4. J Chromatogr B Biomed Appl. 1994. PMID: 7820269

4

Does AIDS impair the absorption of antituberculosis agents?

Taylor B, Smith PJ. Taylor B, et al. Among authors: smith pj. Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5. Int J Tuberc Lung Dis. 1998. PMID: 9712282

5

The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.

McIlleron H, Gabriels G, Smith PJ, Fourie PB, Ellard GA. McIlleron H, et al. Among authors: smith pj. Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S329-35; discussion S351-2. Int J Tuberc Lung Dis. 1999. PMID: 10593713 Clinical Trial.

6

Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.

McIlleron H, Wash P, Burger A, Folb P, Smith P. McIlleron H, et al. Int J Tuberc Lung Dis. 2002 Apr;6(4):356-61. Int J Tuberc Lung Dis. 2002. PMID: 11936746

7

The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.

Pillai G, Ellard GA, Smith PJ, Fourie PB. Pillai G, et al. Among authors: smith pj. Int J Tuberc Lung Dis. 2001 Aug;5(8):691-5. Int J Tuberc Lung Dis. 2001. PMID: 11495257 Clinical Trial.

8

Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.

Gabriels GA, McIlleron H, Smith PJ, Folb PI, Fourie PB. Gabriels GA, et al. Among authors: smith pj. Int J Tuberc Lung Dis. 2007 Feb;11(2):181-8. Int J Tuberc Lung Dis. 2007. PMID: 17263289

9

Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.

Amlabu V, Mulligan C, Jele N, Evans A, Gray D, Zar HJ, McIlleron H, Smith P. Amlabu V, et al. Int J Tuberc Lung Dis. 2014 May;18(5):528-30. doi: 10.5588/ijtld.13.0730. Int J Tuberc Lung Dis. 2014. PMID: 24903787 Free PMC article. Clinical Trial.

10

Pyrazinamide plasma concentrations in young children with tuberculosis.

McIlleron H, Willemse M, Schaaf HS, Smith PJ, Donald PR. McIlleron H, et al. Among authors: smith pj. Pediatr Infect Dis J. 2011 Mar;30(3):262-5. doi: 10.1097/inf.0b013e3181fbefe1. Pediatr Infect Dis J. 2011. PMID: 21416694

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,282 results

Search Page

Filters